Vandana Singh
·
July 22, 2025
Benzinga
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.
read more
July 30, 2025
July 16, 2025
Bloomberg
July 23, 2025
June 9, 2025
Barchart